Pharmafile Logo

Frontera London

- PMLiVE

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech

Keytruda windfall helps research charity invest

- PMLiVE

Liver cancer failure dents Opdivo potential by $1bn, says analyst

Adds to bad news of forced Otezla sell-off

- PMLiVE

The social dilemma: is it time for pharma to join the party?

Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun

MIT reveals new pill to deliver insulin

A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...

Blue Latitude Health

- PMLiVE

Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

Success against placebo, but fails to outperform Dupixent

- PMLiVE

Pfizer’s Talzenna cleared for breast cancer in Europe

Fourth to market aims to carve out niche

Sanofi reception

Sanofi sheds jobs in R&D restructuring

New R&D chief diverting funds to new therapy areas

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links